Arovella Therapeutics Limited

ASX:ALA Stock Report

Market Cap: AU$173.5m

Arovella Therapeutics Management

Management criteria checks 2/4

Arovella Therapeutics' CEO is Michael Baker, appointed in Jan 2020, has a tenure of 4.5 years. total yearly compensation is A$528.03K, comprised of 61.5% salary and 38.5% bonuses, including company stock and options. directly owns 0.62% of the company’s shares, worth A$1.08M. The average tenure of the management team and the board of directors is 1.5 years and 2.8 years respectively.

Key information

Michael Baker

Chief executive officer


Total compensation

CEO salary percentage61.5%
CEO tenure4.5yrs
CEO ownership0.6%
Management average tenure1.5yrs
Board average tenure2.8yrs

Recent management updates

Recent updates

We're Hopeful That Suda Pharmaceuticals (ASX:SUD) Will Use Its Cash Wisely

Jul 01
We're Hopeful That Suda Pharmaceuticals (ASX:SUD) Will Use Its Cash Wisely

CEO Compensation Analysis

How has Michael Baker's remuneration changed compared to Arovella Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a


Sep 30 2023n/an/a


Jun 30 2023AU$528kAU$325k


Mar 31 2023n/an/a


Dec 31 2022n/an/a


Sep 30 2022n/an/a


Jun 30 2022AU$604kAU$303k


Mar 31 2022n/an/a


Dec 31 2021n/an/a


Sep 30 2021n/an/a


Jun 30 2021AU$403kAU$275k


Mar 31 2021n/an/a


Dec 31 2020n/an/a


Sep 30 2020n/an/a


Jun 30 2020AU$385kAU$124k


Compensation vs Market: Michael's total compensation ($USD353.29K) is about average for companies of similar size in the Australian market ($USD300.30K).

Compensation vs Earnings: Michael's compensation has been consistent with company performance over the past year.


Michael Baker





Dr. Michael Baker serves as Chief Executive Officer of Arovella Therapeutics Limited (formerly known as Suda Pharmaceuticals Ltd). since January 2, 2020 and served as its Executive Chairman until July 1, 2...

Leadership Team

Michael Baker
CEO, MD & Director4.5yrsAU$528.03k0.62%
A$ 1.1m
Nicole van der Weerden
Chief Operating Officer1.5yrsAU$384.76k0.078%
A$ 135.7k
Tim Luscombe
Company Secretary & CFOless than a yearno datano data
Michelle Long
Administration Managerless than a yearno datano data
Tony Macintyre
GM & CTO3.5yrsno datano data


Average Tenure

Experienced Management: ALA's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.

Board Members

Michael Baker
CEO, MD & Director4.5yrsAU$528.03k0.62%
A$ 1.1m
Gary Phillips
Independent Non-Executive Director2yrsAU$74.34k0.069%
A$ 119.2k
Elizabeth Stoner
Non-Executive Director2.7yrsAU$241.97k0.073%
A$ 125.9k
Thomas Duthy
Non-Executive Chair1.3yrsAU$29.60k0.45%
A$ 783.3k
Gianpietro Dotti
Member of Scientific Advisory Boardless than a yearno datano data
Debora Barton
Independent Non-Executive Director2.9yrsAU$145.09k0.025%
A$ 43.4k
Reuben Benjamin
Member of Scientific Advisory Board2.9yrsno datano data
John Maher
Member of Scientific Advisory Board2.8yrsno datano data
Anastasios Karadimitris
Chairman of Scientific Advisory Boardno datano datano data


Average Tenure


Average Age

Experienced Board: ALA's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.